Company: TYRA
Filing Date: 2025-04-18
Form Type: DEF 14A
Source: 0001193125-25-085709
Chunk: 34

Company: Tyra Biosciences, Inc.
Filing Date: 2025-04-18
Form: DEF 14A
Chunk 34
---
 |
| Chief Executive Officer     |     |      | 2023 |     |        | 608,400 |     |        | 3,560,469 |     |                | 456,300 |     |              | 950 |     |       | 4,626,119 |
| Douglas Warner, M.D.(4)     |     |      | 2024 |     |        | 165,625 |     |        | 4,469,114 |     |                |  90,465 |     |              | 313 |     |       | 4,725,517 |
| Chief Medical Officer       |     |      |      |     |        |         |     |        |           |     |                |         |     |              |     |     |       |           |
| Daniel Bensen               |     |      | 2024 |     |        | 475,900 |     |        | 1,917,556 |     |                | 260,793 |     |              | 950 |     |       | 2,655,199 |
| Chief Operating Officer     |     |      | 2023 |     |        | 457,600 |     |        | 1,186,823 |     |                | 274,560 |     |              | 950 |     |       | 1,919,933 |

| (1) | The amounts reported in the “Option Awards” column represent the aggregate grant date fair value of the stock options awarded to our named executive officers during the applicable fiscal year, calculated in accordance with Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the grant date fair value of the awards reported in this column are set forth in Note 7 to our financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on March 27, 2025. The amounts reported in this column reflect the accounting cost for the awards and do not reflect the actual economic value that will be realized by our named executive officers upon the exercise of the stock options or the sale of the Common Stock underlying such awards. See “—Narrative to Summary Compensation Table—Equity-Based Incentive Awards.” |

| (2) | The amounts disclosed represent performance bonuses earned